Lonzaplans to open two additional manufacturing sites to expand the conjugation facility.
The expansion of additional two manufacturing suites aims for the development and manufacturing infrastructure for clinical and commercial supply. The new production suites are connected to theexisting conjugation facility.
The manufacturing suite covers approximately 1500m2 and adds 30 per cent additional capacity for clinical and commercial supply. Moreover, an additional 5000m2 space is designed for logistics, storage, and other supporting infrastructure to provide an optimal workflow.Therefore, the highly flexible setup makes use of single-use, stainless steel, and hybrid concepts for bioconjugation processes.
The laboratory space is extended to double the analytical and process development capacity.
With the opening of a new manufacturing suite expands the bioconjugation capacityand thus offering highly flexible solutions for a broad range of customers.
The construction of the bioconjugation capacity is scheduled to be fully operational for customers in the first half of 2022.